Research and development

The Purdue/Mundipharma/Napp independent associated companies were among the first to develop controlled release technology and successfully apply it to many useful medicines. Since the launch of Phyllocontin Continus tablets in 1974, the Companies' expertise in controlled release systems has enabled many valuable drugs to outperform their original potential by simplifying dosage and improving patient compliance.

The companies currently employ over 500 scientists in the US, UK, Germany and Canada who work in research and development. This international research collaboration is at the forefront of new controlled release delivery technology.  Developments include systems that utilise slow release spheroids within capsules, and controlled release resin formulations, which gradually release a drug within the digestive tract.

The International Molecular Discovery group operates across local company divisions and through an extensive network of collaborative ventures with both industrial and academic partners. The independent associated companies have combinatorial chemistry and monoclonal antibody technologies.

Medical

The independent associated companies' medical departments employ physicians and scientists who carry out and monitor clinical studies to test the efficacy and safety of new products. They support registration applications throughout the world. Our doctors maintain close contact with world opinion leaders in their respective therapeutic areas.

Regulatory Affairs

The companies have extensive regulatory affairs in the UK and North America. Experts in regulatory affairs maintain close contacts with health authorities worldwide. This experience has brought success in obtaining marketing approvals throughout Europe, the US and Asia.